Metagenomi, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Metagenomi, Inc., a precision genetic medicines company, files an amendment to its S-1 registration statement, aiming to raise approximately $100 million in an initial public offering and list its common stock on the Nasdaq Global Select Market under the symbol 'MGX'.
NASDAQ
S-1/A: Metagenomi Files for IPO, Aiming to Raise Up to $100 Million for Genetic Medicine Development
Metagenomi, a precision genetic medicines company, has filed an S-1/A form to register 6,250,000 shares of common stock for an initial public offering, with an expected price between $15.00 and $17.00 per share.